Improved Synthesis of Anxiolytic, Anticonvulsant, and Antinociceptive α2/α3-GABA(A)-ergic Receptor Subtype Selective Ligands as Promising Agents to Treat Anxiety, Epilepsy, and Neuropathic Pain

Abstract

An improved synthesis of the anxiolytic, anticonvulsant, and antinociceptive compounds: Hz-166, and its bioisosteres 1,2,4-oxadiazole (MP-III-080) and 1,3-oxazole (KRM-II-81) were synthesized in higher yields and with more facile purification methods (crystallization, etc.) in multigram quantities without column chromatography. In the synthesis of KRM-II-81, an alternative procedure was employed using the selective reducing reagent, potassium diisobutyl-tert-butoxyaluminum hydride (PDBBA), to prepare the desired C(3)-aldehyde in the absence of N(5)–C(6) imine reduction in good yield on a 20 gram scale.

Key words

GABA_AR - benzodiazepines - anxiety - epilepsy - neuropathic pain - large scale - imine - selective reduction

• References

• 1 Richter L. de Graaf C. Sieghart W. Varagic Z. Morzinger M. de Esch IJ. Ecker GF. Ernst M. Nat. Chem. Biol. 2012; 8: 455
• 2 Rudolph U. Mohler H. Curr. Opin. Pharmacol. 2006; 6: 18
• 3 Clayton T. Chen JL. Ernst M. Richter L. Cromer BA. Morton CJ. Ng H. Kaczorowski CC. Helmstetter FJ. Furtmuller R. Ecker G. Parker MW. Sieghart W. Cook JM. Curr. Med. Chem. 2007; 14: 2755
• 4 Rudolph U. Crestani F. Benke D. Brunig I. Benson JA. Fritschy JM. Martin JR. Bluethmann H. Mohler H. Nature 1999; 401: 796
• 5 Low K. Crestani F. Keist R. Benke D. Brunig I. Benson JA. Fritschy JM. Rulicke T. Bluethmann H. Mohler H. Rudolph U. Science 2000; 290: 131
• 6 Ninan PT. Insel TM. Cohen RM. Cook JM. Skolnick P. Paul SM. Science 1982; 218: 1332
• 7 Mendelson WB. Owen C. Skolnick P. Paul SM. Martin JV. Ko G. Wagner R. Sleep 1984; 7: 64
• 8 Cook JM. Huang Q. He X. Li X. Yu J. Han D. Lelas S. McElroy JF. US Patent US 7 119 196 B2, 2006
• 9 Mirza NR. Larsen JS. Mathiasen C. Jacobsen TA. Munro G. Erichsen HK. Nielsen AN. Troelsen KB. Nielsen EO. Ahring PK. J. Pharmacol. Exp. Ther. 2008; 327: 954
• 10 Munro G. Lopez-Garcia JA. Rivera-Arconada I. Erichsen HK. Nielsen EO. Larsen JS. Ahring PK. Mirza NR. J. Pharmacol. Exp. Ther. 2008; 327: 969
• 11 Cook JM. Zhou H. Huang S. Sarma PV. V. S. Zhang C. US Patent US 7 618 958 B2, 2009
• 12 Fischer BD. Licata SC. Edwankar RV. Wang ZJ. Huang S. He X. Yu J. Zhou H. Johnson EM. Jr. Cook JM. Furtmuller R. Ramerstorfer J. Sieghart W. Roth BL. Majumder S. Rowlett JK. Neuropharmacology 2010; 59: 612
• 13 Poe MM. Methuku KR. Li G. Verma AR. Teske KA. Stafford DC. Arnold LA. Cramer JW. Jones TM. Cerne R. Krambis MJ. Witkin JM. Jambrina E. Rehman S. Ernst M. Cook JM. Schkeryantz JM. J. Med. Chem. 2016; 59: 10800
• 14 Witkin JM. Cerne R. Wakulchik MS. J. Gleason SD. Jones TM. Li G. Arnold LA. Li JX. Schkeryantz JM. Methuku KR. Cook JM. Poe MM. Pharmacol. Biochem. Behav. 2017; 157: 35
• 15 Fischer BD. Schlitt RJ. Hamade BZ. Rehman S. Ernst M. Poe MM. Li G. Kodali R. Arnold LA. Cook JM. Brain Res. Bull. 2017; 131: 62
• 16 Atack JR. Wafford KA. Street LJ. Dawson GR. Tye S. Van Laere K. Bormans G. Sanabria-Bohorquez SM. De Lepeleire I. de Hoon JN. Van Hecken A. Burns HD. McKernan RM. Murphy MG. Hargreaves RJ. J. Psychopharmacol. 2011; 25: 314
• 17 Clayton T. Poe MM. Rallapalli S. Biawat P. Savic MM. Rowlett JK. Gallos G. Emala CW. Kaczorowski CC. Stafford DC. Arnold LA. Cook JM. Int. J. Med. Chem. 2015; 430248
• 18 Rivas FM. Stables JP. Murphree L. Edwankar RV. Edwankar CR. Huang S. Jain HD. Zhou H. Majumder S. Sankar S. Roth BL. Ramerstorfer J. Furtmüller R. Sieghart W. Cook JM. J. Med. Chem. 2009; 52: 1795
• 19 Di Lio A. Benke D. Besson M. Desmeules J. Daali Y. Wang ZJ. Edwankar R. Cook JM. Zeilhofer HU. Neuropharmacology 2011; 60: 626
• 20 Namjoshi OA. Wang Z.-j. Rallapalli SK. Johnson EM. Johnson Y.-T. Ng H. Ramerstorfer J. Varagic Z. Sieghart W. Majumder S. Roth BL. Rowlett JK. Cook JM. Bioorg. Med. Chem. 2013; 21: 93
• 21 Patani GA. LaVoie EJ. Chem. Rev. 1996; 96: 3147
• 22 Langmuir I. J. Am. Chem. Soc. 1919; 41: 1543
• 23 Burger A. Prog. Drug Res. 1991; 37: 287
• 24 Boström J. Hogner A. Llinàs A. Wellner E. Plowright AT. J. Med. Chem. 2012; 55: 1817
• 25 Cook J. Huang S. Edwankar R. Namjoshi OA. Wang ZJ. US Patent US 8 835 424 B2, 2014
• 26 Cook J. Poe MM. Methuku KR. Li G. PCT Int. Appl. WO 2016/154031 A1, 2016; US Patent Appl. US 2018/0065967 A1, 2018
• 27 Shimazaki T. Iijima M. Chaki S. Eur. J. Pharmacol. 2004; 501: 121
• 28 Lewter LA. Fisher JL. Siemian JN. Methuku KR. Poe MM. Cook JM. Li J.-X. ACS Chem. Neurosci. 2017; 8: 1305
• 29 Yang J. Teng Y. Ara S. Rallapalli S. Cook JM. Synthesis 2009; 145687
• 30 Shenming H. Synthesis of Optically Active Subtype Selective Benzodiazepine Receptor Ligands: Ph. D. Thesis. University of Wisconsin-Milwaukee; Milwaukee: 2007
• 31 Fryer IR. Walser A. Eur. Pat. Appl EP 1985135770, 1985 ; Chem. Abstr. 1985, 103: 160545
• 32 Fryer IR. Gu ZQ. Wang CG. J. Heterocycl. Chem. 1991; 28: 1661
• 33 Watjen F. Baker R. Engelstoff M. Herbert R. MacLeod A. Knight A. Merchant K. Moseley J. Saunders J. J. Med. Chem. 1989; 32: 2282
• 34 Kayukova LA. Pharm. Chem. J. 2005; 39: 539
• 35 Li G. Stephen MR. Kodali R. Zahn NM. Poe MM. Tiruveedhula VV. N. P. B. Huber AT. Schussman MK. Qualmann K. Panhans CM. Raddatz NJ. Baker DA. Prevot TD. Banasr M. Sibille E. Arnold LA. Cook JM. ARKIVOC 2018; (iv): 158
• 36 Fylaktakidou KC. Hadjipavlou-Litina DJ. Litinas KE. Varella EA. Nicolaides DN. Curr. Pharm. Des. 2008; 14: 1001
• 37 Mussoni L. Poggi A. De Gaetano G. Donati MB. Br. J. Cancer 1978; 37: 126
• 38 Greenblatt DJ. Matlis R. Scavone JM. Blyden GT. Harmatz JS. Shader RI. Br. J. Clin. Pharmacol. 1985; 19: 373
• 39 Drach SV. Litvinovskaya RP. Khripach VA. Chem. Heterocycl. Compd. 2000; 36: 233
• 40 Turchi IJ. Dewar MJ. S. Chem. Rev. 1975; 75: 389
• 41 van Leusen AM. Hoogenboom BE. Siderius H. Tetrahedron Lett. 1972; 2369
• 42 Chae MJ. Song JI. An DK. Bull. Korean Chem. Soc. 2007; 28: 2517
• 43 Boussonnière A. Bénéteau R. Lebreton J. Dénès F. Eur. J. Org. Chem. 2013; 7853
• 44 Zakharkin LI. Khorlina IM. Tetrahedron Lett. 1962; 619